

What immuno-oncology can mean for patients

Francesco de Lorenzo
President of ECPC

19 November 2014




Nothing About Us Without Us!

ECPC: "Nothing about us, without us"

- **Representing 349 cancer patient groups in 46 countries**
- **All cancers** – common and rare
- **Run and governed by patients**
- Promoting **timely access** to appropriate prevention, screening, early diagnosis, treatment and care for all cancer patients
- **Reducing disparity** and inequity across the EU
- Encouraging the **advance of cancer research & innovation**
- Increasing cancer patients' **influence** over European health and **research policy**
- Members of the **European Commission Expert Group on Cancer Control**

European Cancer Patient Coalition's Activities





- Today, across all cancer types, only **1 in 3 people** with cancer will survive more than 5 years
- Immuno-oncology therapies have been recognised as a **breakthrough** for cancer patients, offering many patients the hope of

What is different about immuno-oncology therapies?

They target the body's **immune system**, not the tumour itself

They enable the immune system to selectively **recognise** and **attack** cancer cells

They give long-lasting **memory** to the immune system, so that it can continually adapt to the cancer over time and provide durable, long-term response to the cancer

Immuno-oncology therapies may work across **a large number of cancer types.**

Already available to patients with:


Advanced melanoma

Prostate cancer

They target
the body's
immune system,
not the tumour
itself

Clinical trials are ongoing in some of the most difficult-to-treat cancers, including:

- Bladder
- Breast
- Colorectal
- Kidney
- Leukaemia
- Lung
- Lymphoma
- Ovarian
- Pancreatic



They enable
the immune system
to selectively
recognise and **attack**
cancer cells

As a result, **side-effects associated with immuno-oncology therapies are manageable** as compared to many other cancer therapies.

They give long-lasting **memory** to the immune system, so that it can continually adapt to the cancer over time and provide durable, long-term response to the cancer

This translates into **long-term, quality survival.**

Many patients for whom prognosis was previously very poor may now be in remission for a very long time.


Long-term quality survival means:

- Being able to lead a full life;*
- Being able to look after one's children and family;*
- Being able work and engage in social activities;*
- Being able to maintain independence and not feel one is a burden on one's family.*

Our understanding of how immuno-oncology therapies work is evolving rapidly.

Therefore, patients must have **accurate, up-to-date information**

- To ensure access of all patients to immuno-oncology therapies;
- To help them have a meaningful dialogue with their doctors;
- To help them understand the role that these therapies may play in their treatment.



**EUROPEAN
CANCER
PATIENT
COALITION**

What is immuno-oncology?

A guide for patients

Why this leaflet?

Scientists worldwide have been studying the role the **immune system** can play in fighting cancer for several decades.

However, it was only recently that **immuno-oncology therapies** were found that provide lasting anti-cancer benefits to patients who previously had very few treatment options available to them.^{1,2} These therapies represent a 'breakthrough'³ in cancer therapy and they have the potential to revolutionise the way we treat many forms of cancer.³

This leaflet aims to help patients understand what these new therapies are, how they differ from existing treatments, and what role they will play in years to come.

ECPC and Immuno-Oncology

ECPC has a long time interest in immuno-oncology, organising the first meeting on this topic in December 2013 together with MEP Philippe de Backer.

ECPC **co-chaired** the **European Expert Group on Immuno-Oncology** that drafted the Guidelines launched today as well as the Guide to Patients .

In 2015, ECPC will also launch an on-line Academy on Immuno-Oncology.

Thank for your attention

email : francesco.delorenzo@ecpc.org



@cancereu



European Cancer Patient Coalition



ECPCtv